Coston, Mc Isaac & Partners Anavex Life Sciences Corp. Transaction History
Coston, Mc Isaac & Partners
- $259 Million
- Q1 2024
A detailed history of Coston, Mc Isaac & Partners transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Coston, Mc Isaac & Partners holds 200 shares of AVXL stock, worth $902. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$902
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AVXL
# of Institutions
159Shares Held
31.6MCall Options Held
910KPut Options Held
1.35M-
State Street Corp Boston, MA7.3MShares$32.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$30 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.41MShares$19.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.71MShares$7.72 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC851KShares$3.84 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $352M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...